FADS2 has been shown to play a key role in FA desaturation in different cancer cell lines and primary tumors that are resistant to SCD inhibitors, and simultaneous blocking of both SCD and FADS2 resulted in a significant tumor reduction in hepatocellular and lung carcinoma xenografts [60]. This evidence concerns the gene FADS2 and neoplasm.